

Flying Blind

Social media toolkit

September 10, 2025

Key messages and assets to support communication and advocacy of our Flying Blind report on the landscape of global R&D for endometriosis, polycystic ovary syndrome (PCOS) and uterine fibroids.

Contents

Key links	1
Key messages	2
Social media posts	2
General	
Endometriosis	
Polycystic Ovary Syndrome (PCOS)	
Uterine Fibroids	3
Systemic issues / funders	3
Infographics	3
Videos	

Key links

Report: www.impactglobalhealth.org/insights/report-library/flying-blind

Impact Global Health handles

Bluesky: @impactglobalhealth.bsky.social

• LinkedIn: Impact Global Health



Key messages

- Endometriosis, PCOS and uterine fibroids affect hundreds of millions of women worldwide, yet these conditions remain underfunded and poorly understood.
- In 2023, combined R&D funding for these three conditions was just \$50m 17 times less than the rest of LMIC-applicable R&D for SRH conditions, and only 6% of SRH-specific R&D.
- Endometriosis received the most funding (\$28m), but still far below what's needed; uterine fibroids (\$12m) and PCOS (\$10m) fared even worse.
- Funding is dominated by the US NIH (86–99% of funding), leaving progress vulnerable to policy shifts.
- Most investment goes to basic research (59–86%), underscoring how little is known and how far we are from effective diagnostics or cures.
- Product pipelines are dominated by repurposed medicines that only provide symptomatic relief; innovation in diagnostics and treatments is scarce.
- Despite some recent momentum in endometriosis R&D, fragile gains are at risk without new, diversified investment.

Social media posts

General

- Millions live with endometriosis, PCOS or uterine fibroids yet funding for all three combined was only \$50m in 2023. Impact Global Health's [tag] Flying Blind shows how underinvestment keeps innovation stalled. tinyurl.com/IGHflyingblind

Endometriosis

• Endometriosis is estimated to affect up 1 in 10 women globally, yet funding into R&D for the condition was only \$28m in 2023. Read Flying Blind to understand the product pipeline and innovation might bring. tinyurl.com/IGHflyingblind

Polycystic Ovary Syndrome (PCOS)

 PCOS affects up to 1 in 5 women of reproductive age yet R&D funding was only \$10m in 2023. This poorly understood condition relies on many repurposed treatments and none offer a cure. Flying Blind reveals the urgent need for targeted R&D→ tinyurl.com/IGHflyingblind

impactglobalhealth.org Page 2



Uterine Fibroids

We uterine fibroids are estimated to affect 20-70% of women globally but the R&D pipeline is small. Read Impact Global Health's [tag] new report Flying Blind for more insights: tinyurl.com/IGHflyingblind

Funders

The US NIH provides up to 99% of funding for R&D into endometriosis, PCOS and fibroids. This dependency is risky as a shift in US policy could eradicate any progress. Flying Blind highlights the need for more diversified investors and investments: tinyurl.com/IGHflyingblind

General

• Women's health has been sidelined for too long. Flying Blind shows that even modest investments can drive progress but current levels leave millions behind. It's time to fund innovations that meet women's needs: tinyurl.com/IGHflyingblind

Infographics

 Infographic on endometriosis R&D

Flyings Blind

Endowering the property of the

 Infographic on PCOS R&D



 Infographic on uterine fibroids R&D



impactglobalhealth.org Page 3



Videos

 Key messages on endometriosis R&D



 Key messages on uterine fibroids R&D



Key messages on PCOS R&D



For questions or support please contact:

Emmanuelle Bomo, Communications Lead: ebomo@impactgh.org

impactglobalhealth.org Page 4